

INTEGRATED BIOPHARMA INC
 Form 5
 August 14, 2008

FORM 5

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0362
 Expires: January 31, 2005
 Estimated average burden hours per response... 1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
 Form 3 Holdings Reported Form 4 Transactions Reported

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
YUSIBOV VIDADI

2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [INBP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
 06/30/2008

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O IBIOPHARMA, INC., 9
 INNOVATION WAY, SUITE 100
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Reporting (check applicable line)

NEWARK, DE 19711

Form Filed by One Reporting Person
 Form Filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	02/07/2007	^	A4(1)	10,200 A	\$ 0 (1) 13,900 (2)	D	^
Restricted Stock Unit	11/16/2007	^	A4(3)	10,500 A	\$ 0 (3) 13,900 (2)	D	^

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
					(A)	(D)	Date Exercisable	Expiration Date	Title	
Stock Options	\$ 6.8	02/07/2007	Â	A4 <u>(4)</u>	4,800	Â	Â <u>(4)</u>	02/07/2017	Common Stock	4,800
Stock Options	\$ 6.21	05/06/2007	Â	A4 <u>(5)</u>	1,500	Â	Â <u>(5)</u>	05/06/2017	Common Stock	1,500
Stock Options	\$ 3.05	11/16/2007	Â	A4 <u>(6)</u>	4,500	Â	Â <u>(6)</u>	11/02/2017	Common Stock	4,500

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
YUSIBOV VIDADI C/O IBIOPHARMA, INC. 9 INNOVATION WAY, SUITE 100 NEWARK,Â DEÂ 19711	Â X	Â	Â	Â

Signatures

/s/ VIDADI
YUSIBOV

08/14/2008

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On February 7, 2007, the Reporting Person was granted 10,200 Restricted Stock Units as compensation for serving as an independent director of the Issuer. Each Restricted Stock Unit consists of a right to the issuance of one share of common stock, par value \$.002 ("Common Stock"). The Restricted Stock Units are subject to a three-year vesting period.

(2) Represents the amount of securities beneficially owned by the Reporting Person as of the date hereof.

On November 16, 2007, the Reporting Person was granted 10,500 Restricted Stock Units as compensation for serving as an independent director of the Issuer. Each Restricted Stock Unit consists of a right to the issuance of one share of Common Stock. The Restricted Stock Units are subject to a one-year vesting period.

(4)

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 5

On February 7, 2007, the Reporting Person was granted a stock option to purchase 4,800 shares of Common Stock at an exercise price of \$6.80 per share as compensation for serving as an independent director of the Issuer. These stock options are subject to a three-year vesting period, with an initial annual vesting date of December 20, 2007.

- (5) On May 16, 2007, the Reporting Person was granted a stock option to purchase 1,500 shares of Common Stock at an exercise price of \$6.21 per share as compensation for serving on a Scientific Advisory Board of the Issuer. These stock options are subject to a three-year vesting period, with an initial annual vesting date of May 16, 2008.

- (6) On November 16, 2007, the Reporting Person was granted a stock option to purchase 4,500 shares of Common Stock at an exercise price of \$3.05 per share as compensation for serving as an independent director of the Issuer. These stock options are subject to a one-year vesting period, with an initial monthly vesting date of December 16, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.